Helmut Salih M.D.

Helmut Salih studied medicine at Ludwig-Maximilian University Munich (1990 to 1997).

From 1997-1998), he was resident in Hematology and Oncology at the University Hospital Großhadern, Munich, where he became involved in the the first clinical trial with bispecific CD28 antibodies in man, headed by Gundram Jung.

He then served for two years as postdoc in the Immunology Department of the Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA (1999-2000).

From 2001-2005 he completed his residency in Hematology, Oncology at Eberhard Karls University, Tübingen, Germany and thereafter served as consultant physician in oncology (2005-2019). From 2007-2014, he was Associated Professor of Tübingen University.

Since 2014 he is Chair for Translational Immunology at Tübingen University and serves as Head of the Clinical Collaboration Unit (CCU) Translational Immunology within the German Cancer Consortium (DKTK) at DKFZ.

Since 2019 he is Medical Director of the CCU Translational Immunology, Department of Internal Medicine, University Hospital Tübingen.

Helmut Salih is author on more than 200 scientific publications and inventor on >10 patents. His research focuses on novel strategies for cancer immunotherapy, and he has translated >10 self-developed therapeutic concepts until the stage of clinical evaluation, serving as coordinating investigator in the respective trials.

In 2023, he founded TWYCE GmbH together with Gundram Jung and Martin Pflügler.